AbbVie (Netherlands)

Recent papers from AbbVie (Netherlands)

1. Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational studyArthritis Research & Therapy · 2025
2. Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivityTranslational Psychiatry · 2024
3. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseasesLara D. Veeken · 2023
4. Systems genomics in age-related macular degenerationExperimental Eye Research · 2022
5. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases · 2019
6. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritisRMD Open · 2018
7. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature reviewBMC Nephrology · 2018
8. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate aloneRMD Open · 2017
9. Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The NetherlandsDrugs & Therapy Perspectives · 2016